Creo Medical Group PLC Update on US Clinical Education Programme (2330U)
March 28 2019 - 2:00AM
UK Regulatory
TIDMCREO
RNS Number : 2330U
Creo Medical Group PLC
28 March 2019
Creo Medical Group plc
("Creo" or the "Company")
Update on US Clinical Education Programme
Creo Medical Group plc (AIM: CREO), a medical device company
focused on the emerging field of surgical endoscopy, announces that
additional gastrointestinal (GI) surgeons in the US have performed
successful treatments in both upper and lower GI cases using Creo's
Speedboat device powered by the Company's CROMA Advanced Energy
platform.
Following the first successful treatment of patients in the US
with Speedboat, announced in January 2019, Speedboat has now been
used successfully by a further four GI surgeons. Furthermore, at a
recent scientific conference, Speedboat was demonstrated during a
live case to an audience of leading therapeutic GI endoscopists.
During the same conference, many of these leading therapeutic
endoscopists were able to get a hands-on introductory experience
with Speedboat in a training environment with excellent feedback,
in particular with regards to the safety profile Speedboat provides
the endoscopist.
This brings the total number of doctors now trained in the US to
six at five hospitals across the East and West coasts. Creo will be
working very closely with these centres as further cases are
carried out, along with providing a continuing Clinical Education
programme.
All of these initial users of Speedboat form part of the Creo's
education led strategy to identify and develop the training centres
of the future, not only in the US market but also throughout our
distribution network. This considered and targeted approach
represents our investment in the future of the business. Speedboat
is the first device of a range of GI devices to be cleared for use
with the CROMA Advanced Energy platform that uniquely harnesses the
use of bipolar radiofrequency energy for precise tissue dissection
along with microwave energy for highly controlled coagulation and
tissue ablation.
Dr Zacharias Tsiamoulos, Consultant in Gastroenterology and
Specialist in GI Endoscopy at the East Kent University Hospitals
Foundation Trust, has been overseeing training to the US surgeons
on the techniques required to successfully undertake procedures
utilising Speedboat. Speedboat helps to reduce the risks associated
with alternative open, laparoscopic and existing endoscopic
procedures, reduces the length of stay in hospital for the patient,
and reduces the cost of treatment by transferring therapy from the
operating theatre to the endoscopy room.
Patients have now been successfully treated using the Speedboat
device in the UK, South Africa, Mainland Europe and the US.
Craig Gulliford, Chief Executive Officer of Creo, commented:
"A training-led commercialisation strategy is key to the
successful roll-out of our products and we are delighted with the
progress that we are making with clinicians in the US. Our Clinical
Education Programme ensures that the first adopters of our
technology, having been carefully mentored by our own doctors and
endoscopy nurses, can deliver consistently high standards in this
emerging field of surgical endoscopy, safeguarding quality control
and ensuring best patient outcomes."
Creo Medical Group plc
Richard Rees (CFO) +44 (0)129 160 6005
Cenkos Securities +44 (0)20 7397 8900
Stephen Keys / Mark Connelly (NOMAD)
Michael Johnson / Russell Kerr (Sales)
Walbrook PR Ltd Tel: +44 (0)20 7933 8780 or creo@walbrookpr.com
Paul McManus Mob: +44 (0)7980 541 893
Helen Cresswell Mob: +44 (0)7841 917 679
About Creo Medical
Creo Medical, founded in 2003, is a medical device company
focused on the development and commercialisation of minimally
invasive surgical devices, by bringing advanced energy to
endoscopy. The Company's mission is to improve patient outcomes by
applying microwave and RF energy to surgical endoscopy. Creo has
developed CROMA, an electrosurgical advanced energy platform that
combines bipolar radiofrequency for precise localised cutting and
microwave for controlled coagulation. This technology provides
clinicians with flexible, accurate and controlled surgical
solutions.
The Company's strategy is to bring its CROMA platform to market
through a suite of medical devices which the Company has designed,
initially for the emerging field of GI therapeutic endoscopy, an
area with high unmet needs. The CROMA platform will be developed
further for bronchoscopy and laparoscopy procedures. The Company
believes its technology can impact the landscape of surgery and
endoscopy by providing a safer, less-invasive and more
cost-efficient option of treatment.
For more information about Creo Medical please see our website,
investors.creomedical.com
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
MSCEAKDXALSNEFF
(END) Dow Jones Newswires
March 28, 2019 03:00 ET (07:00 GMT)
Creo Medical (LSE:CREO)
Historical Stock Chart
From Apr 2024 to May 2024
Creo Medical (LSE:CREO)
Historical Stock Chart
From May 2023 to May 2024